ArticleEFORT open reviews2026
Intravenous tranexamic acid shows limited efficacy in arthroscopic shoulder surgery: a systematic review and meta-analysis of randomized-controlled trials.
Article in EFORT open reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The use of intravenous (IV) tranexamic acid (TXA) in arthroscopic shoulder surgery remains controversial. This meta-analysis aimed to evaluate the efficacy of IV TXA in improving perioperative outcomes during shoulder arthroscopy. Methods: The review process was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive systematic search was conducted in PubMed, Embase, Cochrane Library, and Web of Science from inception to February 2025. Randomized-controlled trials (RCTs) comparing IV TXA with group without TXA in patients undergoing arthroscopic shoulder surgery were included. Data were synthesized using random-effects models, with results presented as weighted mean differences (WMDs) and standardized mean differences (SMDs), with 95% confidence intervals (CIs). Results: Eleven RCTs involving 904 patients were included. Overall, seven trials were rated as high quality, while four trials were rated as moderate quality. Pooled results showed no statistically differences between TXA and control groups in terms of visual clarity (SMD: 0.25, 95% CI: -0.21 to 0.70), visual analog scale score (WMD: -0.33, 95% CI: -0.76 to 0.10), operative time (WMD: -4.48 min, 95% CI: -10.25 to 1.28), irrigation volume (SMD: -0.14, 95% CI: -0.52 to 0.24), estimated blood loss (SMD: -0.62, 95% CI: -1.86 to 0.61), and mean arterial pressure (WMD: -0.10 mmHg, 95% CI: -3.05 to 2.86). No complications were reported in either group across six studies. Conclusions: Current evidence does not support a significant clinical benefit of IV TXA in arthroscopic shoulder surgery. Further high-quality RCTs are needed to clarify its role under standardized protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.